Amoéba Company

Management Committee

Jean-François DOUCET, General Deputy

Jean-François DOUCET has over 25 years’ experience in corporate finance and administration. After ten years as an audit and transactional consultant at PwC, Jean-François was appointed Chief Financial Officer of a number of companies in the chemicals and healthcare sectors (BASF, Gibaud, Ossür, etc.). Throughout his career, he has acquired extensive experience of operational, strategic and international issues in commercial and industrial environments. He has also been involved in corporate divestment and transformation projects. Jean-François is a graduate of EM Lyon, where he specialised in finance.

Jean-Baptiste EBERST, Regulatory Affairs Director

Jean-Baptiste EBERST has more than 10 years of experience in Regulatory Affairs in various regulated fields, including health and pest control products. Before joining Amoéba in 2015, he worked in the pharmaceutical (Sanofi Pasteur, Merck Serono) and medical device (Integra LifeSciences) industries, where he was in charge of the regulatory management of product portfolios in various regions (USA, Europe, Canada, Middle East). He has a strong knowledge in regulatory product approval and regulatory compliance assurance. Jean-Baptiste is a pharmacist, graduated from the University of Strasbourg.


Sandrine TROUSSIEUX, Scientific Director

Sandrine TROUSSIEUX, Doctor of Science, has more than 20 years of experience in research and development in the field of environmental microbiology. She has published 25 articles in peer-reviewed scientific papers. Before joining Amoéba, she was responsible for a sequencing platform and the realization of research projects in microbial ecology in an engineering school (Ecole Centrale de Lyon). Sandrine TROUSSIEUX is a graduate of Claude Bernard University in Lyon.

Hervé Testeil, Industrial Director

Hervé Testeil has acquired more than 24 years of experience in the pharmaceutical and medical device industry. From his beginnings in structural calculations for aeronautics and railways, to the Industrial Management of Amoéba, he has held various operational positions (Production, Supply-Chain, Quality and Regulatory Affairs, Industrial Development). He has also managed the strategic transformation of numerous laboratories (FAMAR, BOIRON, MERIAL, ALCYON, GIBAUD, J&J MEDICAL, DELPHARM, KISKO INTERNATIONAL, DÔME PHARMA, PHYTEO, etc.). Hervé Testeil holds a Master’s degree in Mechanical Design from the University of Lille.


Our story

The patent discovery

Amoéba is an innovative company, created in July 2010 by Fabrice PLASSON.

When the company was founded, its initial objective was to develop a patent from the University of Lyon. This patent is based on a single-celled microscopic organism isolated from a natural environment, the amoeba Willaertia magna C2c Maky, which is able to fight against the proliferation of legionella.

Amoéba then began the development of a new biological biocide for the industrial control of legionella, free amoebae and biofilm.

A successful IPO

In July 2015, Amoéba was listed on the regulated market of Euronext, Paris.

This successful IPO allowed the company to raise €13.2M.

Thanks to this, Amoéba has been able to develop its scientific, industrial and commercial expertise around the amoeba. We are now able to offer technological solutions and products in a wide range of applications.

A diversification of the offer

Amoéba has developed two technologies.

The first one is used for the treatment of water, surfaces and chronic wounds and uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky.

The second technology is dedicated to agriculture and more precisely to biocontrol for the treatment of phytopathogenic microorganisms using the lysed (non-living) form of this same amoeba.

Our mission

At the crossroads of environmental protection and public health issues, we are developing a three-fold scientific, industrial and commercial expertise. The company is developing around multiple applications using the amoeba Willaertia magna C2c Maky in the prevention of microbiological risk for water treatment, human wounds and plant protection.

Our commitment

With the growing awareness of the fragility or scarcity of key natural resources such as water, air and food, Amoéba wants to be a major player in the biological revolution in the treatment of these crucial resources, with a global and integrated vision of environmental and health issues. By offering world-class natural solutions that are alternative or complementary to chemical treatments, more respectful of ecosystems, technologically efficient and economically viable, we want to have a concrete impact on the new environmental balances and on tomorrow’s society.


Our values

Make it bold.

We develop disruptive technologies to bring out new alternative solutions, so taking risks is an integral part of our project.

Make it simple.

We always aim for scientific and technological excellence, and we emphasize simplicity and pragmatism in our relationships and operating processes.

Make it happen.

Saying what we are going to do and doing what we said we would do to make our projects a reality, deliver the expected results and be trustworthy over the long term.

Make it fun.

With an ambitious and demanding entrepreneurial project, friendliness, solidarity and efficiency go hand in hand. Having fun at work is a state of mind that everyone must maintain.

Our vision

By 2024, we want to have demonstrated our usefulness and influence by being commercially present in three areas of application: water treatment, agriculture and human health. In this way, we hope to have paved the way for further research and development of alternatives to chemical treatments of our key resources.

Want to join the Amoeba adventure ?

To make our common project grow, join us by sending us your application !